AUS
NZ
UK
CA
USA
IND
Highlights
- Legal & General Group Plc reduced its stake in Amphastar Pharmaceuticals during the fourth quarter.
- Multiple institutions, including Huntington National Bank and TD Private Client Wealth LLC, increased their holdings.
- Amphastar continues to lead in injectable and intranasal therapies within the pharmaceutical industry.
Amphastar Pharmaceuticals (NASDAQ:AMPH) is a biopharmaceutical company engaged in the development, manufacture, and marketing of generic and proprietary injectable, inhalation, and intranasal products. The company is known for offering accessible and essential medications, including treatments for asthma, diabetes-related hypoglycemia, and opioid overdose. Its portfolio includes widely used products such as BAQSAMI, Primatene Mist, Enoxaparin, and Naloxone—demonstrating its commitment to public health and emergency care solutions.
Institutional Activity and Capital Shifts
Recent filings highlight varied institutional movements around Amphastar Pharmaceuticals. Legal & General Group Plc reduced its holdings during the fourth quarter, reflecting a modest shift in its position. However, other institutions moved in the opposite direction. Huntington National Bank expanded its stake significantly, while TD Private Client Wealth LLC and KBC Group NV also increased their holdings.
These changes point to diverse strategic approaches among capital managers regarding exposure to pharmaceutical companies with product lines focused on acute care and high-demand therapeutic categories. With more than half of the company’s equity held by institutions, Amphastar maintains strong visibility across healthcare-focused portfolios.
Market Performance and Financial Profile
The company’s recent trading activity shows moderate movement within its fifty-two week range. It opened at a stable level during recent sessions, aligning with its historical pricing metrics. Financial indicators such as the debt-to-equity ratio, current ratio, and quick ratio reflect a healthy balance sheet and operational stability.
Amphastar’s earnings-related ratios—including its P/E and PEG values—are consistent with peer companies in the generic and specialty pharmaceutical segments. Its moderate beta suggests limited volatility, making it a stable presence within biopharmaceutical equity holdings.
Operational Focus and Product Innovation
Amphastar’s product strategy centers on therapeutic categories that address urgent medical needs. Its ability to develop, manufacture, and distribute generic and branded medications supports both accessibility and treatment continuity in critical care scenarios. The company’s focus on respiratory, emergency, and metabolic disorders enhances its relevance in public health contexts.
Its manufacturing capabilities and regulatory alignment allow it to respond to market demands efficiently, supporting domestic and international supply chains. Amphastar’s strategic direction continues to align with healthcare priorities that emphasize affordability, availability, and treatment efficacy.
